The University of Chicago Header Logo

Connection

James Howard Tonsgard to Adult

Back to Details
This is a "connection" page, showing publications James Howard Tonsgard has written about Adult.
James Howard Tonsgard
Connection Strength
0.146
Adult
  1. Qualitative aspects of pain in children and adults with neurofibromatosis type 1 and plexiform neurofibromas: Causes, consequences, and communication. J Health Psychol. 2026 Mar; 31(4):1562-1574.
    View in: PubMed
    Score: 0.014
  2. Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. J Neurooncol. 2025 Jul; 173(3):751-757.
    View in: PubMed
    Score: 0.014
  3. Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings. J Patient Rep Outcomes. 2025 Apr 30; 9(1):46.
    View in: PubMed
    Score: 0.014
  4. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro Oncol. 2023 08 03; 25(8):1498-1506.
    View in: PubMed
    Score: 0.013
  5. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S50-S63.
    View in: PubMed
    Score: 0.011
  6. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 03 01; 39(7):797-806.
    View in: PubMed
    Score: 0.011
  7. Dural Ectasia in Neurofibromatosis 1: Case Series, Management, and Review. Neurosurgery. 2020 05 01; 86(5):646-655.
    View in: PubMed
    Score: 0.010
  8. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454.
    View in: PubMed
    Score: 0.010
  9. CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology. 1998 Jun; 50(6):1755-60.
    View in: PubMed
    Score: 0.009
  10. Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet. 1997 Nov 28; 73(1):80-6.
    View in: PubMed
    Score: 0.009
  11. High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. Hum Mutat. 2015 Nov; 36(11):1052-63.
    View in: PubMed
    Score: 0.007
  12. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr; 17(4):596-603.
    View in: PubMed
    Score: 0.007
  13. Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine. Neurology. 1993 Nov; 43(11):2362-8.
    View in: PubMed
    Score: 0.006
  14. Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation. Mod Pathol. 2013 Jul; 26(7):930-43.
    View in: PubMed
    Score: 0.006
  15. Late-onset neurofibromatosis in a liver transplant recipient. Int J Dermatol. 2000 May; 39(5):376-9.
    View in: PubMed
    Score: 0.003
  16. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet. 1999 Jun 11; 84(5):413-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.